Possible impact of HLA class I and class II on malignancies driven by a single germ-line BRCA1 mutation.
BCRA1 mutation
HLA class I
HLA class II
breast cancer
ovarian cancer
Journal
International journal of immunogenetics
ISSN: 1744-313X
Titre abrégé: Int J Immunogenet
Pays: England
ID NLM: 101232337
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
revised:
13
07
2023
received:
09
05
2023
accepted:
21
07
2023
medline:
11
9
2023
pubmed:
28
7
2023
entrez:
28
7
2023
Statut:
ppublish
Résumé
This study provides the first immunogenetic preliminary evidence that specific human leucocyte antigen (HLA) class I and class II alleles and haplotypes may be relevant for BRCA1 c.5263_5264insC driven oncogenesis. Observed HLA associations might have practical implications for establishment of predictive markers for the response to immunotherapies in malignancies driven by this germ-line mutation.
Substances chimiques
Histocompatibility Antigens Class I
0
Histocompatibility Antigens Class II
0
BRCA1 protein, human
0
BRCA1 Protein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
243-248Subventions
Organisme : National Science Fund, Ministry of Education and Science (MES) of Bulgaria
ID : KP-06-H23/4
Organisme : National Science Fund, Ministry of Education and Science (MES) of Bulgaria
ID : KP-06-H41/2
Organisme : Biobanking at Molecular Medicine Center
ID : DO1-285
Organisme : Biobanking at Molecular Medicine Center
ID : DO1-395
Organisme : Biobanking at Molecular Medicine Center
ID : DO1-302
Organisme : Biobanking at Molecular Medicine Center
ID : DO1-165
Organisme : MES of Bulgaria
Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Atoum, M. F., Tanashat, R. Q., & Mahmoud, S. A. (2013). Negative association of the HLA-DQB1*02 allele with breast cancer development among Jordanians. Asian Pacific Journal of Cancer Prevention, 14(11), 7007-7010. https://doi.org/10.7314/APJCP.2013.14.11.7007
Aureli, A., Canossi, A., Del Beato, T., Buonomo, O., Rossi, P., Roselli, M., Papola, F., Marziani, B., & Sconocchia, G. (2020). Breast cancer is associated with increased HLA-DRB1*11:01 and HLA-DRB1*10:01 allele frequency in a population of patients from central Italy. Immunological Investigations, 49(5), 489-497. https://doi.org/10.1080/08820139.2020.1737539
Balmana, J., Diez, O., Rubio, I. T., & Cardoso, F., Group EGW. (2011). BRCA in breast cancer: ESMO clinical practice guidelines. Annals of Oncology, 22(6), vi31-34. https://doi.org/10.1093/annonc/mdr373
Bateman, A. C., & Howell, W. M. (1999). Human leukocyte antigens and cancer: Is it in our genes? Journal of Pathology, 188(3), 231-236. https://doi.org/10.1002/(SICI)1096-9896(199907)188:3%3c231::AID-PATH325%3e3.0.CO;2-A
Borst, J., Ahrends, T., Babala, N., Melief, C. J. M., & Kastenmuller, W. (2018). CD4(+) T cell help in cancer immunology and immunotherapy. Nature Reviews Immunology, 18(10), 635-647. https://doi.org/10.1038/s41577-018-0044-0
Cantu de Leon, D., Perez-Montiel, D., Villavicencio, V., Garcia, C. A., Mohar, B. A., Acuna-Alonzo, V., López-Tello, A., Vargas-Alarcón, G., Barquera, R., Yu, N., Yunis, E. J., & Granados, J. (2009). High resolution human leukocyte antigen (HLA) class I and class II allele typing in Mexican mestizo women with sporadic breast cancer: Case-control study. BMC Cancer, 9, 48. https://doi.org/10.1186/1471-2407-9-48
Chaudhuri, S., Cariappa, A., Tang, M., Bell, D., Haber, D. A., Isselbacher, K. J., Finkelstein, D., Forcione, D., & Pillai, S. (2000). Genetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRB1*11 may represent protective alleles. PNAS, 97(21), 11451-11454. https://doi.org/10.1073/pnas.97.21.11451
Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., Greenbaum, B., Carroll, J., Garon, E., Hyman, D. M., Zehir, A., Solit, D., Berger, M., Zhou, R., Rizvi, N. A., & Chan, T. A. (2018). Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science, 359(6375), 582-587. https://doi.org/10.1126/science.aao4572
Dodova, R. I., Mitkova, A. V., Dacheva, D. R., Hadjo, L. B., Vlahova, A. I., Hadjieva, M. S. T., Valev, S. S., Caulevska, M. M., Popova, S. D., Popov, I. E., Dikov, T. I., Sedloev, T. A., Ionkov, A. S., Timcheva, K. V., Christova, S. L., Kremensky, I. M., Mitev, V. I., & Kaneva, R. P. (2015). Spectrum and frequencies of BRCA1/2 mutations in Bulgarian high risk breast cancer patients. BMC Cancer, 15, 523. https://doi.org/10.1186/s12885-015-1516-2
Dorling, L., Carvalho, S., Allen, J., Gonzalez-Neira, A., Luccarini, C., Wahlström, C., Pooley, K. A., Parsons, M. T., Fortuno, C., Wang, Q., Bolla, M. K., Dennis, J., Keeman, R., Alonso, M. R., Álvarez, N., Herraez, B., Fernandez, V., Núñez-Torres, R., … Easton, D. F. (2021). Breast cancer risk genes - Association analysis in more than 113,000 women. New England Journal of Medicine, 384(5), 428-439.
Ferreiro-Iglesias, A., Lesseur, C., Mckay, J., Hung, R. J., Han, Y., Zong, X., Christiani, D., Johansson, M., Xiao, X., Li, Y., Qian, D. C., Ji, X., Liu, G., Caporaso, N., Scelo, G., Zaridze, D., Mukeriya, A., Kontic, M., Ognjanovic, S., … Brennan, P. (2018). Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity. Nature Communications, 9(1), 3927. https://doi.org/10.1038/s41467-018-05890-2
Gamzatova, Z., Villabona, L., van der Zanden, H., Haasnoot, G. W., Andersson, E., Kiessling, R., Seliger, B., Kanter, L., Dalianis, T., Bergfeldt, K., & Masucci, G. V. (2007). Analysis of HLA class I-II haplotype frequency and segregation in a cohort of patients with advanced stage ovarian cancer. Tissue Antigens, 70(3), 205-13.
Ghaderi, A., Talei, A., Gharesi-Fard, B., Farjadian, S. H., Amirzargar, A., & Vasei, M. (2001). HLA-DBR 1 alleles and the susceptibility of Iranian patients with breast cancer. Pathology Oncology Research, 7(1), 39-41. https://doi.org/10.1007/BF03032603
Grantham, R. (1974). Amino acid difference formula to help explain protein evolution. Science, 185(4154), 862-864. https://doi.org/10.1126/science.185.4154.862
Gun, F. D., Ozturk, O. G., Polat, A., & Polat, G. (2012). HLA class-II allele frequencies in Turkish breast cancer patients. Medical Oncology, 29(2), 466-471. https://doi.org/10.1007/s12032-011-9873-4
Haabeth, O. A. W., Tveita, A. A., Fauskanger, M., Schjesvold, F., Lorvik, K. B., Hofgaard, P. O., Omholt, H., Munthe, L. A., Dembic, Z., Corthay, A., & Bogen, B. (2014). How do CD4(+) T cells detect and eliminate tumor cells that either lack or express MHC class II molecules? Frontiers in Immunology, 5, 174. https://doi.org/10.3389/fimmu.2014.00174
Ho, P. J., Khng, A. J., Tan, B. K.-T., Tan, E. Y., Tan, S.-M., Tan, V. K. M., Lim, G. H., Aronson, K. J., Chan, T. L., Choi, J.-Y., Dennis, J., Ho, W.-K., Hou, M.-F., Ito, H., Iwasaki, M., John, E. M., Kang, D., Kim, S.-W., Kurian, A. W., … Li, J. (2022). Relevance of the MHC region for breast cancer susceptibility in Asians. Breast Cancer (Tokyo, Japan), 29(5), 869-879. https://doi.org/10.1007/s12282-022-01366-w
Ivanova, M., Creary, L. E., Al Hadra, B., Lukanov, T., Mazzocco, M., Sacchi, N., Ameen, R., Al-Shemmari, S., Moise, A., Ursu, L. D., Constantinescu, I., Vayntrub, T., Fernández-Vina, M. A., Shivarov, V., & Naumova, E. (2019). 17th IHIW component “immunogenetics of ageing” - New NGS data. Human Immunology, 80(9), 703-713. https://doi.org/10.1016/j.humimm.2019.07.287
Iwahori, K. (2020). Cytotoxic CD8(+) lymphocytes in the tumor microenvironment. Advances in Experimental Medicine and Biology, 1224, 53-62. https://doi.org/10.1007/978-3-030-35723-8_4
James, L. M., & Georgopoulos, A. P. (2022). Immunogenetic clustering of 30 cancers. Scientific Reports, 12(1), 7235. https://doi.org/10.1038/s41598-022-11366-7
Kaneko, K., Ishigami, S., Kijima, Y., Funasako, Y., Hirata, M., Okumura, H., Shinchi, H., Koriyama, C., Ueno, S., Yoshinaka, H., & Natsugoe, S. (2011). Clinical implication of HLA class I expression in breast cancer. BMC Cancer, 11, 454. https://doi.org/10.1186/1471-2407-11-454
Kelly, A., & Trowsdale, J. (2019). Genetics of antigen processing and presentation. Immunogenetics, 71(3), 161-170. https://doi.org/10.1007/s00251-018-1082-2
Kobayashi, H., Ohno, S., Sasaki, Y., & Matsuura, M. (2013). Hereditary breast and ovarian cancer susceptibility genes (review). Oncology Reports, 30(3), 1019-1029. https://doi.org/10.3892/or.2013.2541
Kreiter, S., Vormehr, M., Van De Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., Tadmor, A. D., Schoenberger, S. P., Huber, C., Türeci, Ö., & Sahin, U. (2015). Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature, 520(7549), 692-696. https://doi.org/10.1038/nature14426
Kuchenbaecker, K. B., Neuhausen, S. L., Robson, M., Barrowdale, D., Mcguffog, L., Mulligan, A. M., Andrulis, I. L., Spurdle, A. B., Schmidt, M. K., Schmutzler, R. K., Engel, C., Wappenschmidt, B., Nevanlinna, H., Thomassen, M., Southey, M., Radice, P., Ramus, S. J., Domchek, S. M., Nathanson, K. L., … Antoniou, A. C. (2014). Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 16(6), 3416. https://doi.org/10.1186/s13058-014-0492-9
Lavado, R., Benavides, M., Villar, E., Ales, I., Alonso, A., & Caballero, A. (2005). The HLA-B7 allele confers susceptibility to breast cancer in Spanish women. Immunology letters, 101(2), 223-225.
Leong, P. P., Muhammad, R., Ibrahim, N., Cheong, S. K., & Seow, H. F. (2011). HLA-A and breast cancer in West Peninsular Malaysia. Medical Oncology, 28(1), 51-56. https://doi.org/10.1007/s12032-009-9414-6
Mahmoodi, M., Nahvi, H., Mahmoudi, M., Kasaian, A., Mohagheghi, M.-A., Divsalar, K., Nahavandian, B., Jafari, A., Ansarpour, B., Moradi, B., Aghamohammadi, A., & Amirzargar, A. (2012). HLA-DRB1, -DQA1 and -DQB1 allele and haplotype frequencies in female patients with early onset breast cancer. Pathology Oncology Research, 18(1), 49-55. https://doi.org/10.1007/s12253-011-9415-6
Marty, R., Kaabinejadian, S., Rossell, D., Slifker, M. J., Van De Haar, J., Engin, H. B., De Prisco, N., Ideker, T., Hildebrand, W. H., Font-Burgada, J., & Carter, H. (2017). MHC-I genotype restricts the oncogenic mutational landscape. Cell, 171(6), 1272-1283.e15. https://doi.org/10.1016/j.cell.2017.09.050
Marty Pyke, R., Thompson, W. K., Salem, R. M., Font-Burgada, J., Zanetti, M., & Carter, H. (2018). Evolutionary pressure against MHC class II binding cancer mutations. Cell, 175(2), 416-428.e13. https://doi.org/10.1016/j.cell.2018.08.048
Mavaddat, N., Barrowdale, D., Andrulis, I. L., Domchek, S. M., Eccles, D., Nevanlinna, H., Ramus, S. J., Spurdle, A., Robson, M., Sherman, M., Mulligan, A. M., Couch, F. J., Engel, C., Mcguffog, L., Healey, S., Sinilnikova, O. M., Southey, M. C., Terry, M. B., Goldgar, D., … Antoniou, A. C. (2012). Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiology and Prevention Biomarkers, 21(1), 134-147. https://doi.org/10.1158/1055-9965.EPI-11-0775
McAulay, K. A., & Jarrett, R. F. (2015). Human leukocyte antigens and genetic susceptibility to lymphoma. Tissue Antigens, 86(2), 98-113. https://doi.org/10.1111/tan.12604
Michailidou, K., Beesley, J., Lindstrom, S., Canisius, S., Dennis, J., Lush, M. J., Maranian, M. J., Bolla, M. K., Wang, Q., Shah, M., Perkins, B. J., Czene, K., Eriksson, M., Darabi, H., Brand, J. S., Bojesen, S. E., Nordestgaard, B. G., Flyger, H., Nielsen, S. F., … Easton, D. F. (2015). Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nature Genetics, 47(4), 373-380. https://doi.org/10.1038/ng.3242
Narod, S. A., & Salmena, L. (2011). BRCA1 and BRCA2 mutations and breast cancer. Discovery Medicine, 12(66), 445-453.
Oldford, S. A., Robb, J. D., Watson, P. H., & Drover, S. (2004). HLA-DRB alleles are differentially expressed by tumor cells in breast carcinoma. International Journal of Cancer, 112(3), 399-406. https://doi.org/10.1002/ijc.20441
Pierini, F., & Lenz, T. L. (2018). Divergent allele advantage at human MHC genes: Signatures of past and ongoing selection. Molecular Biology and Evolution, 35(9), 2145-2158. https://doi.org/10.1093/molbev/msy116
Rashkin, S. R., Graff, R. E., Kachuri, L., Thai, K. K., Alexeeff, S. E., Blatchins, M. A., Cavazos, T. B., Corley, D. A., Emami, N. C., Hoffman, J. D., Jorgenson, E., Kushi, L. H., Meyers, T. J., Van Den Eeden, S. K., Ziv, E., Habel, L. A., Hoffmann, T. J., Sakoda, L. C., & Witte, J. S. (2020). Pan-cancer study detects genetic risk variants and shared genetic basis in two large cohorts. Nature Communications, 11(1), 4423. https://doi.org/10.1038/s41467-020-18246-6
Reimann, H., Nguyen, A., Sanborn, J. Z., Vaske, C. J., Benz, S. C., Niazi, K., Rabizadeh, S., Spilman, P., Mackensen, A., Ruebner, M., Hein, A., Beckmann, M. W., Van Der Meijden, E. D., Bausenwein, J., Kretschmann, S., Griffioen, M., Schlom, J., Gulley, J. L., Lee, K. L., … Kremer, A. N. (2021). Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy. Journal for ImmunoTherapy of Cancer, 9(6), e002605. https://doi.org/10.1136/jitc-2021-002605
Ren, Y., Cherukuri, Y., Wickland, D. P., Sarangi, V., Tian, S., Carter, J. M., Mansfield, A. S., Block, M. S., Sherman, M. E., Knutson, K. L., Lin, Y., & Asmann, Y. W. (2020). HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer. Oncoimmunology, 9(1), 1744947. https://doi.org/10.1080/2162402X.2020.1744947
Schaid, D. J., Rowland, C. M., Tines, D. E., Jacobson, R. M., & Poland, G. A. (2002). Score tests for association between traits and haplotypes when linkage phase is ambiguous. American Journal of Human Genetics, 70(2), 425-434. https://doi.org/10.1086/338688
Sønderstrup, I. M. H., Jensen, M. B., Ejlertsen, B., Eriksen, J. O., Gerdes, A. M., Kruse, T. A., Larsen, M. J., Thomassen, M., & Laenkholm, A. V. (2019). Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer. Acta Oncologica, 58(3), 363-370. https://doi.org/10.1080/0284186X.2018.1539239
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., Parkhurst, M. R., Yang, J. C., & Rosenberg, S. A. (2014). Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science, 344(6184), 641-645. https://doi.org/10.1126/science.1251102
Veronesi, A., Giacomi, C. D., Magri, M. D., Lombardi, D., Zanetti, M., Scuderi, C., Dolcetti, R., Viel, A., Crivellari, D., Bidoli, E., & Boiocchi, M. (2005). Familial breast cancer: Characteristics and outcome of BRCA 1-2 positive and negative cases. BMC cancer, 5, 70. https://doi.org/10.1186/1471-2407-5-70
Walsh, T., Casadei, S., Coats, K. H., Swisher, E., Stray, S. M., Higgins, J., Roach, K. C., Mandell, J., Lee, M. K., Ciernikova, S., Foretova, L., Soucek, P., & King, M.-C. (2006). Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA, 295(12), 1379-1388. https://doi.org/10.1001/jama.295.12.1379
Yesantharao, P., Wang, W., Ioannidis, N. M., Demehri, S., Whittemore, A. S., & Asgari, M. M. (2017). Cutaneous squamous cell cancer (cSCC) risk and the human leukocyte antigen (HLA) system. Human Immunology, 78(4), 327-335. https://doi.org/10.1016/j.humimm.2017.02.002
Yoshida, K., & Miki, Y. (2004). Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Science, 95(11), 866-871. https://doi.org/10.1111/j.1349-7006.2004.tb02195.x
Zheng, X., Shen, J., Cox, C., Wakefield, J. C., Ehm, M. G., Nelson, M. R., & Weir, B. S. (2014). HIBAG-HLA genotype imputation with attribute bagging. Pharmacogenomics Journal, 14(2), 192-200. https://doi.org/10.1038/tpj.2013.18